<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Fetal hydronephrosis: Etiology and prenatal management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Fetal hydronephrosis: Etiology and prenatal management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Fetal hydronephrosis: Etiology and prenatal management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Laurence S Baskin, MD, FAAP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Louise Wilkins-Haug, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Duncan Wilcox, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal hydronephrosis (dilation of the renal pelvis with or without dilation of the renal calyces) is a common finding on antenatal ultrasound. In most cases, renal pelvic dilation is a transient physiologic state; however, congenital anomalies of the kidney and urinary tract (CAKUT) can present with fetal hydronephrosis due to urinary tract obstruction and vesicoureteral reflux (VUR). These conditions may be associated with impaired renal development and/or put the patient at risk for renal injury.
        </p>
        <p>
         The definition, etiology, and management of fetal hydronephrosis are reviewed here. Postnatal evaluation of fetal hydronephrosis and specific urologic conditions that may present as fetal hydronephrosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6105.html" rel="external">
          "Postnatal evaluation and management of hydronephrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">
          "Congenital ureteropelvic junction obstruction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6581.html" rel="external">
          "Primary megaureter in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6584.html" rel="external">
          "Ectopic ureter"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6575.html" rel="external">
          "Clinical presentation and diagnosis of posterior urethral valves", section on 'Prenatal'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6094.html" rel="external">
          "Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITION AND GRADING
         </span>
        </p>
        <p class="headingAnchor" id="H858010252">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several systems have been developed to diagnose and grade the severity of fetal hydronephrosis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal pelvic diameter (RPD)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Society of Fetal Urology (SFU) criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinary tract dilation (UTD) classification system
        </p>
        <p>
        </p>
        <p>
         However, there is no consensus on the most appropriate grading criteria for the diagnosis of fetal hydronephrosis [
         <a href="#rid2">
          2
         </a>
         ]. In general, the likelihood of having a significant renal anomaly correlates with the severity of hydronephrosis. In our practice, we define fetal hydronephrosis as an RPD &gt;4 mm between 18 and 22 weeks gestation and, in the third trimester, an RPD &gt;10 mm or an SFU grade III or above. We believe that the cutoff point of 10 mm provides a reasonable threshold to detect most fetuses at risk for congenital anomalies of the kidney and urinary tract (CAKUT) and avoids unnecessary testing in cases that are likely due to benign transient hydronephrosis [
         <a href="#rid3">
          3
         </a>
         ]  (
         <a class="graphic graphic_algorithm graphicRef107613" href="/z/d/graphic/107613.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Etiology'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Renal pelvic diameter
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most generally accepted method to define and grade fetal hydronephrosis is ultrasound measurement of the maximum anteroposterior diameter of the fetal renal pelvis, also referred to as RPD, in the transverse plane [
         <a href="#rid4">
          4
         </a>
         ]. Fetal hydronephrosis is graded according to the RPD during the second and/or third trimester of pregnancy. RPD is a measure of collecting system dilation and does not reflect the extent of hydronephrosis and parenchymal changes, such as increased echogenicity, thinning, or caliectasis.
        </p>
        <p>
         Several studies have established normative values for fetal renal size based on gestational age [
         <a href="#rid5">
          5-7
         </a>
         ]. However, there remains a lack of consensus on the threshold RPD that defines clinically significant fetal hydronephrosis, which has a high likelihood for renal pathology requiring postnatal follow-up:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, RPD &gt;10 mm in the second trimester is associated with an increased risk for CAKUT [
         <a href="#rid4">
          4,6,8,9
         </a>
         ]. Fetuses with RPD &gt;15 mm during the third trimester are at the greatest risk for CAKUT [
         <a href="#rid4">
          4,6,8-10
         </a>
         ]. (See
         <a class="local">
          'Congenital anomalies of the kidney and urinary tract (CAKUT)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild renal pelvic dilation, also referred to as pyelectasia, is defined as an RPD ≥4 to 10 mm in the second trimester [
         <a href="#rid4">
          4,6,8,11
         </a>
         ]. Although most cases of mild renal pelvic dilation will resolve and not have a clinical impact on neonatal renal development, there are reports of persistent cases that require postnatal intervention [
         <a href="#rid9">
          9,12-14
         </a>
         ]. Most experts in the field use a value above 4 to 5 mm as the lowest cutoff for fetal hydronephrosis in the second trimester requiring follow-up prenatal ultrasound monitoring.
        </p>
        <p>
        </p>
        <p>
         Gestational age, maternal hydronephrosis, maternal hydration, and degree of bladder distention may affect the RPD [
         <a href="#rid7">
          7,15-17
         </a>
         ]. In addition, varying the minimal RPD threshold for normal can significantly alter the positive predictive value of RPD as a measure of postnatal pathology. Lower cutoffs will be more sensitive in detecting postnatal pathology; however, the tradeoff is in higher false-positive rates and requires more subsequent ultrasound assessments [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2556345845">
         <span class="h2">
          Society of Fetal Urology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The SFU developed criteria for the diagnosis and grading of fetal hydronephrosis based on the degree and site of pelvic dilation, number of calyces seen, and presence and severity of parenchymal atrophy  (
         <a class="graphic graphic_diagnosticimage graphicRef50549" href="/z/d/graphic/50549.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid19">
          19
         </a>
         ]. The SFU grading system focuses on the degree of hydronephrosis in the kidney without directly assessing the state of the ureter and bladder:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade 0 – Normal examination with no dilation of the renal pelvis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade I – Mild dilation of the renal pelvis only  (
         <a class="graphic graphic_diagnosticimage graphicRef68149" href="/z/d/graphic/68149.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade II – Moderate dilation of the renal pelvis including a few calyces
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade III – Dilation of the renal pelvis with visualization of all the calyces, which are uniformly dilated, and normal renal parenchyma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade IV – Similar appearance of the renal pelvis and calyces as grade III, plus thinning of the renal parenchyma  (
         <a class="graphic graphic_diagnosticimage graphicRef62457" href="/z/d/graphic/62457.html" rel="external">
          image 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1555109470">
         <span class="h2">
          Urinary tract dilation classification system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UTD classification, developed by a panel of radiologists, nephrologists, and urologists, is stratified based on gestational age, whether the detection is antenatal or postnatal, and the following six ultrasound findings [
         <a href="#rid20">
          20
         </a>
         ]  (
         <a class="graphic graphic_figure graphicRef101868" href="/z/d/graphic/101868.html" rel="external">
          figure 1
         </a>
         ). Severity of the ultrasound findings is donated by a numerical system (1 through 3, with 3 being the most severe grade), with grading based on the most severe finding.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anterior and posterior RPD
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calyceal dilation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal parenchymal thickness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal parenchymal appearance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bladder abnormalities
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ureteral abnormalities
        </p>
        <p>
        </p>
        <p>
         The UTD system requires more extensive modifiers to determine the level of urinary tract obstruction compared with the SFU system. For example, when communicating that the patient has SFU grade IV ureteropelvic junction (UPJ) hydronephrosis or SFU grade IV ureterovesical junction-type hydronephrosis, there is a clear documentation of the severity and etiology of the urologic anomaly. In contrast, UTD grade 3 requires numerous additional modifiers to communicate the exact diagnosis and severity.
        </p>
        <p>
         Several observational studies have studied the utility of UTD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study that compared the SFU and UTD grading systems, the two methods had similar prognostic ability to predict resolution of prenatal hydronephrosis (defined as RPD &lt;10 mm) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study at four institutions reported fair to moderate interobserver agreement using the UTD grading system, but agreement was higher for the UTD compared with the SFU classification [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study of 447 infants with isolated antenatal hydronephrosis reported that the UTD classification system accurately predicted the risk of chronic kidney disease long term at a median follow-up of nine years [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported incidence of fetal hydronephrosis ranges from 0.6 to 4.5 percent of pregnancies. Differences in reported data may be due to different criteria used to define the disorder and the level of attention to the urinary system by the ultrasonographer [
         <a href="#rid9">
          9,12,24-28
         </a>
         ]. Hydronephrosis occurs approximately twice as often in males as in females. It is bilateral in 20 to 40 percent of cases [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis that included 17 studies, fetal hydronephrosis was identified in 1678 fetuses of 104,572 women (1.6 percent) [
         <a href="#rid9">
          9
         </a>
         ]. However, criteria for the diagnosis of hydronephrosis differed among the included studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one prospective Belgian study of 5643 unselected women, mild fetal hydronephrosis, defined as renal pelvic diameter (RPD) ≥4 mm, was detected by ultrasonography during the second trimester in 4.5 percent of pregnancies [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          ETIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H541563441">
         <span class="h2">
          Transient hydronephrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transient hydronephrosis, by definition, is prenatal dilation (as defined above) of the renal pelvis that resolves over time and is not clinically significant. Transient hydronephrosis is the most common cause of fetal hydronephrosis, with a reported range of 41 to 88 percent of cases [
         <a href="#rid9">
          9
         </a>
         ]. It is thought to be related to a transient narrowing of the ureteropelvic junction (UPJ) or transient fetal folds early in development that resolves or remains stable without clinical implications as the fetus matures. Mild hydronephrosis with renal pelvic diameter (RPD) &lt;6 mm in the second trimester is usually associated with transient hydronephrosis.
        </p>
        <p class="headingAnchor" id="H17635046">
         <span class="h2">
          Congenital anomalies of the kidney and urinary tract (CAKUT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAKUT is a common cause of fetal hydronephrosis that includes both upper/lower urinary tract obstructive (eg, UPJ obstruction) and nonobstructive processes (eg, vesicoureteral reflux [VUR]). It is important to identify these conditions soon after birth as they are potential risk factors for urinary tract infection and chronic kidney disease. (See
         <a class="medical medical_review" href="/z/d/html/6110.html" rel="external">
          "Overview of congenital anomalies of the kidney and urinary tract (CAKUT)", section on 'Association with end-stage kidney disease (ESKD)'
         </a>
         .)
        </p>
        <p>
         In a meta-analysis of 1678 infants diagnosed with fetal hydronephrosis, postnatal evaluation identified CAKUT as the underlying cause of fetal hydronephrosis in one-third of the patients [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Causes of fetal hydronephrosis due to CAKUT include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         UPJ obstruction  (
         <a class="graphic graphic_figure graphicRef55146" href="/z/d/graphic/55146.html" rel="external">
          figure 2
         </a>
         ) was the most common diagnosis and increased in frequency with the severity of hydronephrosis. (See
         <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">
          "Congenital ureteropelvic junction obstruction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VUR was the second most common diagnosis. Moderate to severe reflux (grades III through V) is associated with a greater degree of renal pelvic dilation (RPD &gt;10 mm) both in utero and postnatally  (
         <a class="graphic graphic_figure graphicRef67039" href="/z/d/graphic/67039.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6094.html" rel="external">
          "Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less common causes include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Megaureter  (
         <a class="graphic graphic_figure graphicRef59252" href="/z/d/graphic/59252.html" rel="external">
          figure 4
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/6581.html" rel="external">
          "Primary megaureter in infants and children"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multicystic dysplastic kidney (see
         <a class="medical medical_review" href="/z/d/html/6144.html" rel="external">
          "Kidney cystic diseases in children", section on 'Multicystic dysplastic kidney'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6748.html" rel="external">
          "Prenatal sonographic diagnosis of cystic kidney disease", section on 'Multicystic dysplastic kidney'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ureterocele  (
         <a class="graphic graphic_diagnosticimage graphicRef66351" href="/z/d/graphic/66351.html" rel="external">
          image 4
         </a>
         and
         <a class="graphic graphic_figure graphicRef79559" href="/z/d/graphic/79559.html" rel="external">
          figure 5
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/6586.html" rel="external">
          "Ureterocele"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Posterior urethral valves (PUV)  (
         <a class="graphic graphic_diagnosticimage graphicRef62496" href="/z/d/graphic/62496.html" rel="external">
          image 5
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/6575.html" rel="external">
          "Clinical presentation and diagnosis of posterior urethral valves"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ectopic ureter (see
         <a class="medical medical_review" href="/z/d/html/6584.html" rel="external">
          "Ectopic ureter"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prune-belly syndrome (see
         <a class="medical medical_review" href="/z/d/html/5002.html" rel="external">
          "Prune-belly syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Duplex collecting system  (
         <a class="graphic graphic_diagnosticimage graphicRef72733" href="/z/d/graphic/72733.html" rel="external">
          image 6
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urethral atresia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urogenital sinus and cloacal anomalies
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3129183329">
         <span class="h2">
          Genetic and malformation syndromes
         </span>
        </p>
        <p class="headingAnchor" id="H952670385">
         <span class="h3">
          Down syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild hydronephrosis is a common finding in fetuses with Down syndrome. Studies defining hydronephrosis as RPD ≥4 mm in the second trimester demonstrated that hydronephrosis is greater in Down syndrome compared with normal control fetuses (18 versus 0 to 3 percent, respectively) [
         <a href="#rid27">
          27,31,32
         </a>
         ]. If additional anomalies are noted, diagnostic testing for chromosomal abnormality (eg, Down syndrome) rather than a screening test is appropriate. Amniocentesis to obtain amniocytes for fetal karyotype or microarray will provide a definitive genetic diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/426.html" rel="external">
          "Down syndrome: Overview of prenatal screening", section on 'Diagnostic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2635894988">
         <span class="h3">
          Other anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other nonrenal/urinary tract congenital abnormalities are often associated with fetal hydronephrosis [
         <a href="#rid33">
          33
         </a>
         ]. Hydronephrosis has been reported as part of a multiple malformation syndrome in more than 60 genetic and sporadic malformation syndromes [
         <a href="#rid34">
          34,35
         </a>
         ]. If other fetal structural abnormalities are identified, the fetus is at risk of having a chromosomal abnormality [
         <a href="#rid35">
          35
         </a>
         ]. In this setting, a diagnostic test such as amniocentesis for fetal karyotype or microarray may provide a definitive genetic diagnosis.
        </p>
        <p class="headingAnchor" id="H75090646">
         <span class="h1">
          PRENATAL KIDNEY AND UROLOGIC ULTRASOUND EXAMINATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of fetal hydronephrosis by ultrasound usually occurs in the second trimester with a renal pelvic diameter (RPD) cutoff of ≥4 mm when routine prenatal ultrasonography is performed. Mild hydronephrosis (RPD 4 to 10 mm or Society of Fetal Urology [SFU] grade I or II) can be associated with Down syndrome or other chromosome anomalies. More severe dilation increases the risk of congenital anomalies of the kidney and urinary tract (CAKUT). (See
         <a class="local">
          'Congenital anomalies of the kidney and urinary tract (CAKUT)'
         </a>
         above and
         <a class="local">
          'Genetic and malformation syndromes'
         </a>
         above.)
        </p>
        <p>
         During the ultrasound examination, the appearance of the fetal renal system can vary in both normal fetuses without hydronephrosis and in those with hydronephrosis. Therefore, serial measurements should be taken during each examination [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         If fetal hydronephrosis is detected, the following parameters need to be evaluated by ultrasonography as they may be helpful in determining the cause of hydronephrosis and also identify risk factors for CAKUT. Risk factors associated with CAKUT include increasing severity of hydronephrosis, bilateral hydronephrosis, evidence of post-bladder obstruction (dilated ureter, increase bladder wall thickness), renal parenchymal thinning or echogenicity, and decreased amount of amniotic fluid.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity and persistence of hydronephrosis
         </strong>
         (
         <a class="graphic graphic_diagnosticimage graphicRef68149" href="/z/d/graphic/68149.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef62457" href="/z/d/graphic/62457.html" rel="external">
          image 3
         </a>
         ) – The likelihood of CAKUT increases with the severity of RPD [
         <a href="#rid3">
          3,9,37
         </a>
         ]. Repeat ultrasound performed during the third trimester is more informative in predicting neonatal CAKUT, which may require surgical intervention, as illustrated by the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a meta-analysis of 1678 infants from 17 studies, the following incidences of renal/urinary tract anomalies (eg, ureteropelvic junction [UPJ] obstruction, vesicoureteral reflux [VUR], or posterior urethral valves [PUV]) were noted based on fetal RPD measurements [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mild hydronephrosis (≤7 mm in the second trimester and/or ≤9 mm in the third trimester) – 12 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Moderate hydronephrosis (7 to 10 mm in the second trimester and/or 9 to 15 mm in the third trimester) – 45 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe hydronephrosis (&gt;10 mm in the second trimester and/or &gt;15 mm in the third trimester)  (
         <a class="graphic graphic_diagnosticimage graphicRef62457" href="/z/d/graphic/62457.html" rel="external">
          image 3
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef73308" href="/z/d/graphic/73308.html" rel="external">
          image 7
         </a>
         ) – 88 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a subsequently published review of single-center studies, prenatal resolution was noted in one-quarter of the 1034 cases [
         <a href="#rid38">
          38
         </a>
         ]. At last follow-up (mean age 20.6 months), postnatal hydronephrosis persisted in 10, 25, and 72 percent of patients with mild, moderate, and severe fetal hydronephrosis, respectively. The incidence of surgical intervention based on the severity of fetal hydronephrosis:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mild hydronephrosis – 10 percent; 26 of 267 cases including VUR (n = 14), UPJ obstruction (n = 7), and PUV (n = 2) and 1 case each of cloaca, neurogenic bladder, and ectopic ureterocele
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Moderate hydronephrosis – 24 percent; 11 of 43 cases including VUR (n = 3), UPJ obstruction (n = 5), and PUV (n = 1) and unknown in 2 cases
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe hydronephrosis – 63 percent; 13 of 19 cases including VUR (n = 2) and UPJ obstruction (n = 8) and 1 case each of ureterovesical obstruction, prune-belly syndrome, and unknown
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a prospective French single-center study of cases with severe prenatal hydronephrosis (defined as RPD &gt;10 mm on first fetal examination), 33 of 70 (47 percent) patients had surgical intervention at a median age of five months [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unilateral versus bilateral involvement
         </strong>
         – Bilateral involvement increases the risk of a significant renal abnormality and the risk of impaired postnatal renal function, primarily due to post-bladder obstructive uropathy such as PUV [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ureter
         </strong>
         – Dilation of the ureter can be consistent with VUR or obstructive uropathy distal to the UPJ (eg, ureterocele  (
         <a class="graphic graphic_diagnosticimage graphicRef66351" href="/z/d/graphic/66351.html" rel="external">
          image 4
         </a>
         and
         <a class="graphic graphic_figure graphicRef79559" href="/z/d/graphic/79559.html" rel="external">
          figure 5
         </a>
         ), ectopic ureter, megaureter  (
         <a class="graphic graphic_figure graphicRef59252" href="/z/d/graphic/59252.html" rel="external">
          figure 4
         </a>
         ), or PUV  (
         <a class="graphic graphic_diagnosticimage graphicRef73308" href="/z/d/graphic/73308.html" rel="external">
          image 7
         </a>
         )). (See
         <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">
          "Congenital ureteropelvic junction obstruction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6581.html" rel="external">
          "Primary megaureter in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6584.html" rel="external">
          "Ectopic ureter"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6094.html" rel="external">
          "Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal parenchyma
         </strong>
         – Thinning of the parenchyma and/or cortical cysts indicate injury or impaired development of the renal cortex. An echogenic renal cortex may indicate abnormal renal parenchymal development (dysplasia), which may be associated with VUR or obstructive uropathy. (See
         <a class="medical medical_review" href="/z/d/html/6110.html" rel="external">
          "Overview of congenital anomalies of the kidney and urinary tract (CAKUT)", section on 'Renal dysplasia and hypodysplasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bladder
         </strong>
         – Abnormalities of the bladder, such as increased thickness and trabeculation of the bladder wall, are findings associated with obstructive uropathy distal to the bladder (eg, PUV) [
         <a href="#rid39">
          39
         </a>
         ]. In addition, dilation of the proximal urethra (keyhole sign) may indicate PUV in male fetuses with a thickened bladder wall and hydronephrosis  (
         <a class="graphic graphic_diagnosticimage graphicRef73308" href="/z/d/graphic/73308.html" rel="external">
          image 7
         </a>
         ). Bladder enlargement can be defined as a sagittal diameter (measured in mm) of 2 plus the gestational age (weeks). So, for a fetus that is 24 weeks gestational age, bladder enlargement would be defined as a sagittal diameter ≥26 mm (ie, 2 plus 24) [
         <a href="#rid40">
          40,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6575.html" rel="external">
          "Clinical presentation and diagnosis of posterior urethral valves"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ureteroceles may be visualized in the bladder and can cause bladder outlet obstruction if they insert ectopically within the urethra. (See
         <a class="medical medical_review" href="/z/d/html/6586.html" rel="external">
          "Ureterocele"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amniotic fluid volume
         </strong>
         – Oligohydramnios is consistent with impaired renal function resulting in a decreased production of fetal urine (amniotic fluid). It is a consistent feature of severe renal disease, affecting either both kidneys or a solitary kidney. (See
         <a class="medical medical_review" href="/z/d/html/462.html" rel="external">
          "Assessment of amniotic fluid volume"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6777.html" rel="external">
          "Oligohydramnios: Etiology, diagnosis, and management in singleton gestations", section on 'Clinical manifestations and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of
         <strong>
          urinoma or urinary ascites
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Urinoma
         </strong>
         is a fluid mass formed by extravasated urine encapsulated in the perirenal fascia. Urinomas are secondary to urinary obstruction such as PUV or UPJ obstruction. Although rare, the presence of a fetal urinoma is associated with a nonfunctional dysplastic ipsilateral kidney in 80 percent of cases [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Urinary ascites
         </strong>
         can be secondary to spontaneous or iatrogenic rupture of the bladder and the renal calices due to lower obstruction and increased pressure or, rarely, due to neurogenic bladder.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          PRENATAL MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2616311282">
         <span class="h2">
          Goal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of cases of fetal hydronephrosis are not clinically significant, and, therefore, excessive concern may lead to unnecessary testing of the fetus and newborn infant and anxiety for parents/caregivers and health care providers. The goal of prenatal management is to detect those cases of fetal hydronephrosis that may adversely affect the health of the infant and require antenatal and postnatal evaluation and may benefit postnatally with a timely referral to a pediatric urologist and possible intervention to minimize adverse outcomes, while limiting testing in those cases that are due to a benign, transient condition.
        </p>
        <p class="headingAnchor" id="H71181088">
         <span class="h2">
          Who should be evaluated
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our practice, evaluation is performed for all fetuses with an antenatal ultrasound finding of a renal pelvic diameter (RPD) &gt;4 mm between 18 and 22 weeks gestation and, in the third trimester, RPD &gt;10 mm or a Society of Fetal Urology (SFU) grade III or above. We believe that these cutoff points provide a reasonable threshold to detect most fetuses at risk for congenital anomalies of the kidney and urinary tract (CAKUT) and avoid unnecessary testing in the majority of cases with benign, transient hydronephrosis [
         <a href="#rid3">
          3
         </a>
         ]  (
         <a class="graphic graphic_algorithm graphicRef107613" href="/z/d/graphic/107613.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Definition and grading'
         </a>
         above and
         <a class="local">
          'Prenatal kidney and urologic ultrasound examination'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2907794077">
         <span class="h2">
          Evaluation and management based on initial ultrasound findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management approach depends on the initial ultrasound findings including the presence and nature of associated genitourinary and extrarenal anomalies, severity of hydronephrosis, unilateral versus bilateral involvement, and amniotic fluid volume. Management decision-making is shared with a collaborative maternal-fetal team, consisting of a high-risk obstetrician, fetal ultrasonographer, pediatric urologist, and parents/caregivers of the fetus. We provide parents/caregivers with an explanation of all of the initial ultrasound findings and their potential significance, the next steps of assessment, and if needed, prenatal and postnatal management options. In particular, if the fetal/neonatal prognosis is poor (ie, severe bilateral hydronephrosis, oligohydramnios, and evidence of thin or poorly developed renal parenchyma), legal termination, if possible, can be offered.  (
         <a class="graphic graphic_algorithm graphicRef107613" href="/z/d/graphic/107613.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unilateral hydronephrosis
         </strong>
         – For fetuses with unilateral hydronephrosis defined as an RPD &gt;4 mm in the second trimester, a follow-up ultrasound scan in the third trimester (32 to 34 weeks of gestation) is performed. (See
         <a class="local">
          'Congenital anomalies of the kidney and urinary tract (CAKUT)'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6105.html" rel="external">
          "Postnatal evaluation and management of hydronephrosis", section on 'Subsequent evaluation and management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those with resolution (RPD &lt;10 mm in the third trimester) have a low risk of clinically significant pathology and do not need further antenatal or postnatal evaluation [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those with persistent hydronephrosis RPD &gt;10 mm in the third trimester require postnatal evaluation. In one retrospective review, surgery was performed in approximately one-quarter of affected cases [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, some experts in the field do not repeat a third trimester ultrasound for fetuses with an RPD between 4 and 7 mm in the second trimester but repeat a postnatal ultrasound at three to four weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilateral hydronephrosis or an affected solitary kidney
         </strong>
         – Fetuses with bilateral hydronephrosis or an affected solitary kidney &gt;4 mm and normal amniotic fluid volume have serial ultrasound examinations every two to three weeks after diagnosis to evaluate for progression of dilation and amniotic fluid volume. Follow-up examinations are determined according to the serial ultrasound results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other urologic findings
         </strong>
         – Ureteral dilation, thickened bladder, and/or presence of a ureterocele are findings that may be associated with lower tract urinary obstruction [
         <a href="#rid39">
          39
         </a>
         ]. Although measurement of biochemical markers in amniotic fluid, which is predominantly composed of fetal urine, can be used to assess fetal renal function, these tests are not clinically accurate enough to fully predict postnatal renal function. These tests are as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6106.html" rel="external">
          "Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)", section on 'Amniotic fluid'
         </a>
         and
         <a class="local">
          'Fetal surgery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, because there are no other predictive tools, in our center, we will perform bladder taps in some rare cases of post-bladder obstruction as part of the evaluation to predict renal prognosis for further intervention, including fetal intervention (eg, amnioinfusion and vesicoamniotic shunts). (See
         <a class="local">
          'Fetal surgery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oligohydramnios
         </strong>
         – Management of oligohydramnios (ie, abnormally low amniotic fluid volume) depends on the gestational age of the fetus and is associated with a poor prognosis. The management of oligohydramnios is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6777.html" rel="external">
          "Oligohydramnios: Etiology, diagnosis, and management in singleton gestations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment for other non-genitourinary anomalies and genetic syndromes
         </strong>
         – The finding of mild hydronephrosis should prompt a detailed assessment of fetal anatomy to identify other congenital anomalies. When pyelectasis is identified in an otherwise normal, second-trimester fetus and no previous maternal plasma or serum screening tests for trisomy 21 have been performed, the mother can be offered a cell-free deoxyribonucleic acid (DNA) test to screen for trisomy 21. A normal result indicates a very low risk of an affected fetus, and invasive diagnostic testing is typically avoided in these cases (see
         <a class="medical medical_review" href="/z/d/html/458.html" rel="external">
          "Prenatal screening for common aneuploidies using cell-free DNA", section on 'Secondary cfDNA screening'
         </a>
         ). A serum analyte test instead of a cell-free DNA test is a reasonable alternative for screening. (See
         <a class="medical medical_review" href="/z/d/html/426.html" rel="external">
          "Down syndrome: Overview of prenatal screening", section on 'Second-trimester quadruple test'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Genetic counseling and testing are offered if additional fetal anomalies are detected, in women of advanced maternal age, and in women with abnormal maternal serum screening tests during the first or second trimester. (See
         <a class="medical medical_review" href="/z/d/html/447.html" rel="external">
          "Sonographic findings associated with fetal aneuploidy", section on 'Trisomy 21 (Down syndrome)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H710493">
         <span class="h2">
          Fetal surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there have been several prospective and retrospective studies of antenatal surgery in fetuses with sonographic findings consistent with lower urinary tract obstruction, there is no good evidence that fetal intervention improves renal outcome or long-term patient survival [
         <a href="#rid45">
          45-52
         </a>
         ]. These procedures increase the amount of amniotic fluid, thus potentially improving lung development and survival rate. However, there remains a high rate of fetal demise and chronic renal disease in the survivors, necessitating kidney replacement therapy in almost two-thirds of cases [
         <a href="#rid53">
          53
         </a>
         ]. If antenatal intervention is performed, it should only be performed in select centers with expertise after careful counseling of parents/caregivers on the risk and benefits of the procedure and available information on the neonatal survival and renal outcome. In very rare cases with severe bilateral hydronephrosis due to post-bladder obstruction from posterior urethral valves (PUV), we will consider serial fetal bladder taps for amniotic fluid analysis and, if the prognosis appears favorable, perform a vesicoamniotic shunt.
        </p>
        <p>
         A randomized trial that aimed to determine if percutaneous vesicoamniotic shunting improves survival and renal outcome compared with conservative management could not be completed, due to inability to recruit a sufficient number of cases, only enrolling 31 of the 150 planned pregnancies over a four-year period [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an
         <strong>
          intention-to-treat analysis
         </strong>
         of the 31 enrolled women with singleton pregnancies (16 allocated to vesicoamniotic shunting versus 15 to conservative management), there was a trend for improved survival with shunting at 28 days (relative risk [RR] 1.88, 95% CI 0.71-4.96), one year (RR 2.19, 95% CI 0.69-6.94), and two years of age (RR 2.19, 95% CI 0.69-6.94). Outcomes for the 16 pregnancies allocated to vesicoamniotic shunting were 12 live births, 1 intrauterine death, and 3 terminated pregnancies; for the 15 pregnancies managed conservatively, there were 12 live births, one intrauterine death, and two terminated pregnancies. A significant number of cases did not receive the allocated intervention; 3 of the 16 pregnancies allocated to shunting were managed conservatively, and, conversely, two cases randomized to conservative management had shunting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Due to large crossover, an analysis based on
         <strong>
          treatment
         </strong>
         was performed that showed a larger beneficial effect of shunting on survival at 28 days (RR 3.2, 95% CI 1.06-9.62), one year (RR 4.27, 95% CI 1.07-16.96), and two years of age (RR 4.27, 95% CI 1.07-16.96). Only two offspring who survived to two years of age had normal renal function; both were in the shunt group. Seven complications occurred in six fetuses who were in the shunt group and included spontaneous ruptured membrane, shunt blockage, and dislodgement, which resulted in four pregnancy losses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postnatal diagnoses were made in all 12 perinatal survivors and in three neonates who died and included nine cases of PUV (five in the shunt group and four in the conservative management group), five cases of urethral atresia (four in the shunt group and one in the conservative management group), and one case of urethral syrinx that caused obstruction (in the conservative management group). Diagnostic information was also available in three cases lost during pregnancy: two with urethral atresia and one with PUV.
        </p>
        <p>
        </p>
        <p>
         The results from this study need to be interpreted carefully as four of the fetuses who underwent shunting did not survive and the trial was limited by significantly too few cases and protocol deviation in a substantial number of the enrolled cases. Nevertheless, survival outcome in this study is consistent with the findings of observational studies that suggest that the chance of postnatal normal renal function is low irrespective of whether vesicoamniotic shunting is performed.
        </p>
        <p class="headingAnchor" id="H2737227">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16335.html" rel="external">
          "Patient education: Hydronephrosis in babies (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Fetal hydronephrosis (fetal renal pelvic dilation) is a common finding on antenatal ultrasonography, occurring in 0.6 to 4.5 percent of pregnancies. It can be detected as early as the 12
         <sup>
          th
         </sup>
         week of gestation. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transient hydronephrosis
         </strong>
         is the most common cause of fetal hydronephrosis. Mild hydronephrosis with renal pelvic diameter (RPD) &lt;6 mm in the second trimester is usually associated with transient hydronephrosis. (See
         <a class="local">
          'Transient hydronephrosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Congenital anomalies of the kidney and urinary tract (CAKUT)
         </strong>
         is an important cause of fetal hydronephrosis that should be diagnosed soon after birth as it is associated with chronic kidney disease and urinary tract infection. The two most common CAKUT are ureteropelvic junction (UPJ) obstruction and vesicoureteral reflux (VUR). (See
         <a class="local">
          'Congenital anomalies of the kidney and urinary tract (CAKUT)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In fetuses with
         <strong>
          Down syndrome
         </strong>
         and other genetic and malformation syndromes, mild hydronephrosis is a common finding. (See
         <a class="local">
          'Genetic and malformation syndromes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and grading
         </strong>
         – Although there are many different scoring systems for fetal hydronephrosis, RPD is the most commonly used scoring system based on prenatal ultrasound assessment. Mild hydronephrosis is defined as an RPD ≥4 to 10 mm and more severe hydronephrosis as an RPD &gt;10 mm measured during the second trimester. Fetuses with RPD &gt;15 mm during the third trimester are at the greatest risk for significant renal disease (ie, CAKUT). In our practice, we use a cutoff of &gt;10 mm in the third trimester to determine the need for postnatal evaluation and intervention  (
         <a class="graphic graphic_algorithm graphicRef107613" href="/z/d/graphic/107613.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Prenatal kidney and urologic ultrasound examination'
         </a>
         above and
         <a class="local">
          'Definition and grading'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prenatal renal ultrasound
         </strong>
         – In fetuses with increased RPD, ultrasonographic imaging should assess the severity of hydronephrosis, bilateral or unilateral involvement, renal parenchyma, amount of amniotic fluid, and evidence of ureter or bladder abnormalities. Risk factors associated with CAKUT include increasing severity of hydronephrosis, bilateral hydronephrosis, evidence of post-bladder obstruction (dilated ureter, increase bladder wall thickness), renal parenchymal thinning or echogenicity, and decreased amount of amniotic fluid. (See
         <a class="local">
          'Prenatal kidney and urologic ultrasound examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Goal
         </strong>
         – The goal of prenatal management is to detect those cases of fetal hydronephrosis that may adversely affect the health of the infant and require further evaluation, timely referral to a pediatric urologist if required, and possible intervention to minimize adverse outcomes, while limiting testing in those cases that are due to a benign, transient condition. (See
         <a class="local">
          'Goal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Who should be evaluated
         </strong>
         – In our practice, evaluation is performed for all fetuses with a prenatal ultrasound finding of an RPD &gt;4 mm between 18 and 22 weeks gestation and, in the third trimester, RPD &gt;10 mm. (See
         <a class="local">
          'Who should be evaluated'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management approach
         </strong>
         – The management approach depends on the initial ultrasound findings including the presence and nature of associated genitourinary and extrarenal anomalies, severity of hydronephrosis, unilateral versus bilateral involvement, and amniotic fluid volume. Findings associated with CAKUT include increased severity of hydronephrosis, bilateral hydronephrosis, evidence of post-bladder obstruction (dilated ureter, increase bladder wall thickness), renal parenchymal thinning or echogenicity, and oligohydramnios (decreased amount of amniotic fluid). (See
         <a class="local">
          'Evaluation and management based on initial ultrasound findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In general, fetuses with second-trimester hydronephrosis (RPD &gt;4 mm) should undergo repeat testing in the third trimester to assess progression and identify those who will benefit most from postnatal testing  (
         <a class="graphic graphic_algorithm graphicRef107613" href="/z/d/graphic/107613.html" rel="external">
          algorithm 1
         </a>
         ). We typically perform a repeat examination two to three weeks later in fetuses with bilateral involvement (or an affected solitary kidney) and, in those with unilateral involvement, at 32 to 34 weeks gestation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fetal surgery
         </strong>
         – Data are limited on whether percutaneous vesicoamniotic shunting compared with conservative observation in fetuses with lower urinary tract obstruction improves survival and renal outcome. As a result, we do not suggest that percutaneous vesicoamniotic shunting be routinely performed in fetuses with lower urinary tract obstruction versus observation and monitoring (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If antenatal intervention is performed, it should only be performed in select centers with expertise after careful counseling of parents/caregivers on the risk and benefits of the procedure and available information on the neonatal survival and renal outcome. (See
         <a class="local">
          'Fetal surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4124235160">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Tulin Ozcan, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sidhu G, Beyene J, Rosenblum ND. Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis. Pediatr Nephrol 2006; 21:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanetta VC, Rosman BM, Bromley B, et al. Variations in management of mild prenatal hydronephrosis among maternal-fetal medicine obstetricians, and pediatric urologists and radiologists. J Urol 2012; 188:1935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrés-Jensen L, Jørgensen FS, Thorup J, et al. The outcome of antenatal ultrasound diagnosed anomalies of the kidney and urinary tract in a large Danish birth cohort. Arch Dis Child 2016; 101:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodward M, Frank D. Postnatal management of antenatal hydronephrosis. BJU Int 2002; 89:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chitty LS, Altman DG. Charts of fetal size: kidney and renal pelvis measurements. Prenat Diagn 2003; 23:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott JE, Wright B, Wilson G, et al. Measuring the fetal kidney with ultrasonography. Br J Urol 1995; 76:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odibo AO, Marchiano D, Quinones JN, et al. Mild pyelectasis: evaluating the relationship between gestational age and renal pelvic anterior-posterior diameter. Prenat Diagn 2003; 23:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blachar A, Blachar Y, Livne PM, et al. Clinical outcome and follow-up of prenatal hydronephrosis. Pediatr Nephrol 1994; 8:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee RS, Cendron M, Kinnamon DD, Nguyen HT. Antenatal hydronephrosis as a predictor of postnatal outcome: a meta-analysis. Pediatrics 2006; 118:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scalabre A, Demède D, Gaillard S, et al. Prognostic Value of Ultrasound Grading Systems in Prenatally Diagnosed Unilateral Urinary Tract Dilatation. J Urol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pates JA, Dashe JS. Prenatal diagnosis and management of hydronephrosis. Early Hum Dev 2006; 82:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismaili K, Hall M, Donner C, et al. Results of systematic screening for minor degrees of fetal renal pelvis dilatation in an unselected population. Am J Obstet Gynecol 2003; 188:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grignon A, Filion R, Filiatrault D, et al. Urinary tract dilatation in utero: classification and clinical applications. Radiology 1986; 160:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corteville JE, Gray DL, Crane JP. Congenital hydronephrosis: correlation of fetal ultrasonographic findings with infant outcome. Am J Obstet Gynecol 1991; 165:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson JN, Tice K, Kolm P, Abuhamad AZ. Effect of maternal hydration on fetal renal pyelectasis. Obstet Gynecol 1998; 92:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graif M, Kessler A, Hart S, et al. Renal pyelectasis in pregnancy: correlative evaluation of fetal and maternal collecting systems. Am J Obstet Gynecol 1992; 167:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung VY, Chu WC, Metreweli C. Hydronephrosis index: a better physiological reference in antenatal ultrasound for assessment of fetal hydronephrosis. J Pediatr 2009; 154:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen HT, Herndon CD, Cooper C, et al. The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis. J Pediatr Urol 2010; 6:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernbach SK, Maizels M, Conway JJ. Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. Pediatr Radiol 1993; 23:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen HT, Benson CB, Bromley B, et al. Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system). J Pediatr Urol 2014; 10:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga LH, McGrath M, Farrokhyar F, et al. Society for Fetal Urology Classification vs Urinary Tract Dilation Grading System for Prognostication in Prenatal Hydronephrosis: A Time to Resolution Analysis. J Urol 2018; 199:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson CP, Lee RS, Trout AT, et al. Interobserver and Intra-Observer Reliability of the Urinary Tract Dilation Classification System in Neonates: A Multicenter Study. J Urol 2019; 201:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melo FF, Mak RH, Simões E Silva AC, et al. Evaluation of Urinary Tract Dilation Classification System for Prediction of Long-Term Outcomes in Isolated Antenatal Hydronephrosis: A Cohort Study. J Urol 2021; 206:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dudley JA, Haworth JM, McGraw ME, et al. Clinical relevance and implications of antenatal hydronephrosis. Arch Dis Child Fetal Neonatal Ed 1997; 76:F31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livera LN, Brookfield DS, Egginton JA, Hawnaur JM. Antenatal ultrasonography to detect fetal renal abnormalities: a prospective screening programme. BMJ 1989; 298:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persutte WH, Koyle M, Lenke RR, et al. Mild pyelectasis ascertained with prenatal ultrasonography is pediatrically significant. Ultrasound Obstet Gynecol 1997; 10:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havutcu AE, Nikolopoulos G, Adinkra P, Lamont RF. The association between fetal pyelectasis on second trimester ultrasound scan and aneuploidy among 25,586 low risk unselected women. Prenat Diagn 2002; 22:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Eerde AM, Meutgeert MH, de Jong TP, Giltay JC. Vesico-ureteral reflux in children with prenatally detected hydronephrosis: a systematic review. Ultrasound Obstet Gynecol 2007; 29:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González R, Schimke CM. Ureteropelvic junction obstruction in infants and children. Pediatr Clin North Am 2001; 48:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dias CS, Bouzada MC, Pereira AK, et al. Predictive factors for vesicoureteral reflux and prenatally diagnosed renal pelvic dilatation. J Urol 2009; 182:2440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coco C, Jeanty P. Isolated fetal pyelectasis and chromosomal abnormalities. Am J Obstet Gynecol 2005; 193:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corteville JE, Dicke JM, Crane JP. Fetal pyelectasis and Down syndrome: is genetic amniocentesis warranted? Obstet Gynecol 1992; 79:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontanella F, Maggio L, Verheij JBGM, et al. Fetal megacystis: a lot more than LUTO. Ultrasound Obstet Gynecol 2019; 53:779.
          </a>
         </li>
         <li class="breakAll">
          Limwongse C, Cassidy SB. Syndromes and malformations of the urinary tract. In: Pediatric Neprhology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams and Wilkins, 2004. p.93.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damen-Elias HA, De Jong TP, Stigter RH, et al. Congenital renal tract anomalies: outcome and follow-up of 402 cases detected antenatally between 1986 and 2001. Ultrasound Obstet Gynecol 2005; 25:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persutte WH, Hussey M, Chyu J, Hobbins JC. Striking findings concerning the variability in the measurement of the fetal renal collecting system. Ultrasound Obstet Gynecol 2000; 15:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duncan KA. Antenatal renal pelvic dilatation; the long-term outlook. Clin Radiol 2007; 62:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbosa JA, Chow JS, Benson CB, et al. Postnatal longitudinal evaluation of children diagnosed with prenatal hydronephrosis: insights in natural history and referral pattern. Prenat Diagn 2012; 32:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keefe DT, Kim JK, Mackay E, et al. Predictive accuracy of prenatal ultrasound findings for lower urinary tract obstruction: A systematic review and Bayesian meta-analysis. Prenat Diagn 2021; 41:1039.
          </a>
         </li>
         <li class="breakAll">
          The fetal genitourinary tract. In: Ultrasonography in Obstetrics and Gynecology, 5th ed, Callen PW (Ed), Saunders, Philadelphia 2007. p.647.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maizels M, Alpert SA, Houston JT, et al. Fetal bladder sagittal length: a simple monitor to assess normal and enlarged fetal bladder size, and forecast clinical outcome. J Urol 2004; 172:1995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorincour G, Rypens F, Toiviainen-Salo S, et al. Fetal urinoma: two new cases and a review of the literature. Ultrasound Obstet Gynecol 2006; 28:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassanese G, Travan L, D'Ottavio G, et al. Prenatal anteroposterior pelvic diameter cutoffs for postnatal referral for isolated pyelectasis and hydronephrosis: more is not always better. J Urol 2013; 190:1858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Signorelli M, Cerri V, Taddei F, et al. Prenatal diagnosis and management of mild fetal pyelectasis: implications for neonatal outcome and follow-up. Eur J Obstet Gynecol Reprod Biol 2005; 118:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison MR, Golbus MS, Filly RA, et al. Fetal hydronephrosis: selection and surgical repair. J Pediatr Surg 1987; 22:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassr AA, Shazly SA, Abdelmagied AM, et al. Effectiveness of vesico-amniotic shunt in fetuses with congenital lower urinary tract obstruction: An updated systematic review and meta-analysis. Ultrasound Obstet Gynecol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coplen DE. Prenatal intervention for hydronephrosis. J Urol 1997; 157:2270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crombleholme TM, Harrison MR, Golbus MS, et al. Fetal intervention in obstructive uropathy: prognostic indicators and efficacy of intervention. Am J Obstet Gynecol 1990; 162:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes N, Harrison MR, Baskin LS. Fetal surgery for posterior urethral valves: long-term postnatal outcomes. Pediatrics 2001; 108:E7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris RK, Malin GL, Khan KS, Kilby MD. Systematic review of the effectiveness of antenatal intervention for the treatment of congenital lower urinary tract obstruction. BJOG 2010; 117:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris RK, Ruano R, Kilby MD. Effectiveness of fetal cystoscopy as a diagnostic and therapeutic intervention for lower urinary tract obstruction: a systematic review. Ultrasound Obstet Gynecol 2011; 37:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruano R, Sananes N, Sangi-Haghpeykar H, et al. Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting. Ultrasound Obstet Gynecol 2015; 45:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aulbert W, Kemper MJ. Severe antenatally diagnosed renal disorders: background, prognosis and practical approach. Pediatr Nephrol 2016; 31:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris RK, Malin GL, Quinlan-Jones E, et al. Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. Lancet 2013; 382:1496.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6099 Version 45.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16362721" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22999539" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Variations in management of mild prenatal hydronephrosis among maternal-fetal medicine obstetricians, and pediatric urologists and radiologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27217581" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The outcome of antenatal ultrasound diagnosed anomalies of the kidney and urinary tract in a large Danish birth cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11849184" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Postnatal management of antenatal hydronephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634973" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Charts of fetal size: kidney and renal pelvis measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8535724" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Measuring the fetal kidney with ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14558027" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mild pyelectasis: evaluating the relationship between gestational age and renal pelvic anterior-posterior diameter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8142221" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical outcome and follow-up of prenatal hydronephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882811" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Antenatal hydronephrosis as a predictor of postnatal outcome: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27916713" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prognostic Value of Ultrasound Grading Systems in Prenatally Diagnosed Unilateral Urinary Tract Dilatation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16380224" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prenatal diagnosis and management of hydronephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548224" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Results of systematic screening for minor degrees of fetal renal pelvis dilatation in an unselected population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3526402" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Urinary tract dilatation in utero: classification and clinical applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1872344" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Congenital hydronephrosis: correlation of fetal ultrasonographic findings with infant outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9649109" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of maternal hydration on fetal renal pyelectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1442981" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Renal pyelectasis in pregnancy: correlative evaluation of fetal and maternal collecting systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18675432" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hydronephrosis index: a better physiological reference in antenatal ultrasound for assessment of fetal hydronephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20399145" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8255658" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25435247" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29198999" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Society for Fetal Urology Classification vs Urinary Tract Dilation Grading System for Prognostication in Prenatal Hydronephrosis: A Time to Resolution Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30676479" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Interobserver and Intra-Observer Reliability of the Urinary Tract Dilation Classification System in Neonates: A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34100626" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Evaluation of Urinary Tract Dilation Classification System for Prediction of Long-Term Outcomes in Isolated Antenatal Hydronephrosis: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9059183" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical relevance and implications of antenatal hydronephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2502277" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Antenatal ultrasonography to detect fetal renal abnormalities: a prospective screening programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9263417" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mild pyelectasis ascertained with prenatal ultrasonography is pediatrically significant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12478633" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The association between fetal pyelectasis on second trimester ultrasound scan and aneuploidy among 25,586 low risk unselected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17390310" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Vesico-ureteral reflux in children with prenatally detected hydronephrosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11732127" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ureteropelvic junction obstruction in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19765746" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Predictive factors for vesicoureteral reflux and prenatally diagnosed renal pelvic dilatation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16150267" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Isolated fetal pyelectasis and chromosomal abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1533023" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Fetal pyelectasis and Down syndrome: is genetic amniocentesis warranted?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043466" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Fetal megacystis: a lot more than LUTO.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043466" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Fetal megacystis: a lot more than LUTO.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15660447" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Congenital renal tract anomalies: outcome and follow-up of 402 cases detected antenatally between 1986 and 2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10846771" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Striking findings concerning the variability in the measurement of the fetal renal collecting system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17207695" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Antenatal renal pelvic dilatation; the long-term outlook.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23090854" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Postnatal longitudinal evaluation of children diagnosed with prenatal hydronephrosis: insights in natural history and referral pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34318486" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Predictive accuracy of prenatal ultrasound findings for lower urinary tract obstruction: A systematic review and Bayesian meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34318486" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Predictive accuracy of prenatal ultrasound findings for lower urinary tract obstruction: A systematic review and Bayesian meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15540775" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Fetal bladder sagittal length: a simple monitor to assess normal and enlarged fetal bladder size, and forecast clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16941574" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Fetal urinoma: two new cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23707454" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prenatal anteroposterior pelvic diameter cutoffs for postnatal referral for isolated pyelectasis and hydronephrosis: more is not always better.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15653195" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prenatal diagnosis and management of mild fetal pyelectasis: implications for neonatal outcome and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3302200" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Fetal hydronephrosis: selection and surgical repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27270578" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effectiveness of vesico-amniotic shunt in fetuses with congenital lower urinary tract obstruction: An updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9146651" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prenatal intervention for hydronephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2187354" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Fetal intervention in obstructive uropathy: prognostic indicators and efficacy of intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11433086" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Fetal surgery for posterior urethral valves: long-term postnatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20374578" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Systematic review of the effectiveness of antenatal intervention for the treatment of congenital lower urinary tract obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21374748" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effectiveness of fetal cystoscopy as a diagnostic and therapeutic intervention for lower urinary tract obstruction: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25157756" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26081158" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Severe antenatally diagnosed renal disorders: background, prognosis and practical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23953766" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
